GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline.

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program, sending its shares up 2.2% premarket.

Shares of top coronavirus stock BioNTech (BNTX 5.23%) nicely bucked the general downward trend of the market on Monday. The Germany-based biotech's stock closed more than 5% higher on the day, against the 0.6% rise of the S&P 500 index.

A continued rise in coronavirus cases kept investors interested, but a stronger catalyst was the launch of a stock repurchase program.

Shares of Biogen Inc. bounced 1.7% in premarket trade Monday, after the drugmaker disclosed that it set a new $5.0 billion stock repurchase program, without an expiration date. The new program is in addition to the $1.7 billion remaining under the program set in August 2018.

The pharmaceutical group Celgene has announced it plans to launch a stock repurchase program worth at least $2bn, in the hope to increase back its stock value (Nasdaq), which has decreased over 30% since the beginning of the year and 45% since October 2017.